What we do

DELIVERING
THE PROMISE
OF TARGETED
RNA MEDICINES

NanoGenics is a leading RNA therapeutics company.

We are committed to developing cutting-edge gene silencing and gene enhancing medicines using our proprietary gene delivery technology, LipTide.

Read more about what we do...

OUR PRODUCTS

Our lead product, ECP-105, is our novel glaucoma product that enhances the effectiveness of BLEB surgery.

We expect to get ECP-105 into the clinic in 2025.

Image

Our Delivery

LipTide is a revolutionary peptide nanoscale delivery vehicle invented to mimic a natural virus for targeted delivery of RNA into cells.

With appealing clinical properties, the capability to deliver genetic material to almost any cell type, low toxicity, and repeat dosing, the LipTide technology represents new promise across several therapeutic areas of unmet need.


Read more about what we do...

Image

OUR TEAM

Our unique team of experts brings together

experience, passion and expertise from bench to bedside.


Read more about our team...
Image

Contact Us

Get in touch to learn more about how we are taking our products from concept to clinic.

Dr Simon Newman
Chief Scientific Officer
simon.newman@nanogenics.co.uk


 
Image
Image

Neil Theobald
General Manager
nigel@n4pharma.co.uk